Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Malignant dysgerminomatous germ cell tumor of ovary is the most common form of malignant germ cell tumor of ovary, arising from germ cells in the ovary, usually presenting during adolescence with pelvic mass, fever, vaginal bleeding, and acute abdomen and is characterized by bilaterality (around 10% of cases), association with dysgenetic gonads (5 to 10% of cases), elevated serum lactate dehydrogenase (LDH) and human chorionic gonadotrophin (hCG) (in the presence of syncitiotrophoblasts). Malignant dysgerminomatous germ cell tumor of ovary responds well to chemotherapy, potentially sparing patients from infertility and early mortality.
Biomarker and diagnostic research for malignant dysgerminomatous germ cell tumor of ovary has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for malignant dysgerminomatous germ cell tumor of ovary.
67 publications have been identified in PubMed for malignant dysgerminomatous germ cell tumor of ovary. Research spans Case Report / Case Series (51%), Epidemiology / Natural History (13%), and Review / Meta-Analysis (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 34 | 51% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:41 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Disease patterns and progression |
9 |
13% |
Research summaries | 7 | 10% |
Clinical study results | 7 | 10% |
Laboratory research | 6 | 9% |
Testing and diagnosis research | 4 | 6% |
Zanfagnin V (2026). [PMID: 41887253](https://pubmed.ncbi.nlm.nih.gov/41887253/). *Archives of pathology & laboratory medicine*. [Review / Meta-Analysis]
Wu Q (2026). [PMID: 41663285](https://pubmed.ncbi.nlm.nih.gov/41663285/). *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. [Clinical Trial Publication]
Abida PM (2026). [PMID: 41553048](https://pubmed.ncbi.nlm.nih.gov/41553048/). *Indian journal of pathology & microbiology*. [Case Report / Case Series]
Nakashima M (2026). [PMID: 41292152](https://pubmed.ncbi.nlm.nih.gov/41292152/). *Cancer science*. [Basic Science / Preclinical]
Mukherjee M (2026). [PMID: 41675783](https://pubmed.ncbi.nlm.nih.gov/41675783/). *Annals of medicine and surgery (2012)*. [Case Report / Case Series]
Constantin MM (2026). [PMID: 41815478](https://pubmed.ncbi.nlm.nih.gov/41815478/). *International journal of surgery case reports*. [Diagnostic / Biomarker]
Oğlak SC (2026). [PMID: 41551439](https://pubmed.ncbi.nlm.nih.gov/41551439/). *Case reports in medicine*. [Case Report / Case Series]
Liang J (2026). [PMID: 41317609](https://pubmed.ncbi.nlm.nih.gov/41317609/). *European journal of obstetrics, gynecology, and reproductive biology*. [Case Report / Case Series]
Yoshida S (2026). [PMID: 41806988](https://pubmed.ncbi.nlm.nih.gov/41806988/). *BMJ case reports*. [Case Report / Case Series]
Bae J (2026). [PMID: 41775250](https://pubmed.ncbi.nlm.nih.gov/41775250/). *Journal of gynecologic oncology*. [Clinical Trial Publication]
AI-curated news mentioning malignant dysgerminomatous germ cell tumor of ovary
Updated May 5, 2026
A recent study investigates the impact of lymphadenectomy on survival outcomes in patients with stage I malignant ovarian germ cell tumors. The findings contribute to understanding treatment options for this rare cancer type.
A recent study evaluates the outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors following chemotherapy and surgery. The findings contribute to understanding treatment efficacy and patient prognosis in this rare cancer population.
A recent analysis of the CORSETT database highlights fertility-sparing surgery and treatment strategies for women with malignant ovarian germ cell tumors. This study provides insights into survival outcomes, contributing to the understanding of management options for this rare cancer.